Plantar fibromatosis is a progressive condition with no FDA-approved nonsurgical treatment options. With no official treatment guidelines available, Keenova and its clinical partners are working to ...
Clinical Trials Arena on MSN
Keenova seeks Xiaflex expansion on late-stage rare disease win
If approved, Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.
The drugmaker – which was known as Mallinckrodt beforemerging with Endo and rebranding as Keenova last year – said that ...
Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium ...
Keenova Therapeutics plc, a leading US-focused branded therapeutics company, announced positive results from its phase 3 clinical trial of Xiaflex (collagenase clostridium histolyticum) for the ...
Previously unpublished clinical data support the potential long‑term safety and efficacy of collagenase clostridium histolyticum (CCH) for plantar fibromatosis. The findings will be presented at the ...
DUBLIN, Sept. 21, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar ...
After thriving in the market for more than a decade as the only treatment for Dupuytren's contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could ...
MALVERN, Pa., July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during ...
Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results